Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2003

Open Access 01-12-2003 | Review

Molecular responses to hypoxia in tumor cells

Authors: Manfred Kunz, Saleh M Ibrahim

Published in: Molecular Cancer | Issue 1/2003

Login to get access

Abstract

Highly aggressive, rapidly growing tumors are exposed to hypoxia or even anoxia which occurs as a consequence of inadequate blood supply. Both hypoxia and consecutive hypoxia/reoxygenation exert a variety of influences on tumor cell biology. Among these are activation of certain signal transduction pathways and gene regulatory mechanisms, induction of selection processes for gene mutations, tumor cell apoptosis and tumor angiogenesis. Most of these mechanisms contribute to tumor progression. Therefore, tissue hypoxia has been regarded as a central factor for tumor aggressiveness and metastasis. In this review, we summarize the current knowledge about the molecular mechanisms induced by tumor cell hypoxia with a special emphasis on intracellular signal transduction, gene regulation, angiogenesis and apoptosis. Interfering with these pathways might open perspectives for future innovative treatment of highly aggressive metastasizing tumors.
Appendix
Available only for authorised users
Literature
1.
Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990, 82: 4-6. 10.1093/jnci/82.1.4PubMed
2.
Folkman J, Shing Y: Angiogenesis. J Biol Chem. 1992, 267: 10931-10934.PubMed
3.
Helmlinger G, Yuan F, Dellian M, Jain RK: Interstitial pH and pO2 gradients in solid tumors in vivo: High resolution measurements reveal a lack of correlation. Nat Med. 1997, 3: 177-182.PubMed
4.
Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nature Rev Cancer. 2002, 2: 38-47. 10.1038/nrc704.
5.
Coleman CN, Mitchell JB, Camphausen K: Tumor hypoxia: chicken, egg, or a piece of the farm?. J Clin Oncol. 2002, 20: 610-615.PubMed
6.
Laderoute KR, Webster KA: Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in rat cardiac myocytes. Circ Res. 1997, 80: 336-344.PubMed
7.
Laderoute KR, Mendonca HL, Calaoagan JM, Knapp AM, Giaccia AJ, Stork PJS: Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironment. J Biol Chem. 1999, 274: 12890-12897. 10.1074/jbc.274.18.12890PubMed
8.
Kunz M, Ibrahim S, Koczan D, Thiesen HJ, Koehler HJ, Acker T, Plate KH, Ludwig S, Rapp UR, Broecker EB: Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ. 2001, 12: 137-145.PubMed
9.
Abbruscato TJ, Davis TP: Protein expression of brain endothelial cell E-cadherin after hypoxia/aglycemia: influence of astrocyte contact. Brain Res. 1999, 842: 277-286. 10.1016/S0006-8993(99)01778-3PubMed
10.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996, 379: 88-91.PubMed
11.
Robinson MJ, Copp MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997, 9: 180-186. 10.1016/S0955-0674(97)80061-0PubMed
12.
Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410: 37-40. 10.1038/35065000PubMed
13.
Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR: The ins and outs of Raf kinases. Trends Biochem Sci. 1994, 19: 474-480. 10.1016/0968-0004(94)90133-3PubMed
14.
Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL: MEKKs, GCKs, MLKs, PAKs, TAKs, and Tpls: upstream regulators of the c-Jun amino-terminal kinases. Curr Opin Gen Dev. 1997, 7: 67-74. 10.1016/S0959-437X(97)80111-6.
15.
Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 2000, 103: 239-252.PubMed
16.
Goldberg M, Zhang HL, Steinberg SF: Hypoxia alters the subcellular distribution of the protein kinase C isoforms in neonatal rat ventricular myocytes. J Clin Invest. 1997, 99: 55-61.PubMedCentralPubMed
17.
Kunz M, Bloss G, Gillitzer R, Gross G, Goebeler M, Rapp UR, Ludwig S: Hypoxia/reoxygenation induction of monocyte chemoattractant protein-1 in melanoma cells: involvement of nuclear factor-kappaB, stimulatory protein-1 transcription factors and mitogen-activated protein kinase pathways. Biochem J. 2002, 366: 299-306.PubMedCentralPubMed
18.
Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H: ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001, 2: 222-228. 10.1093/embo-reports/kve046PubMedCentralPubMed
19.
Karin M, Liu Z, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol. 1997, 9: 240-246. 10.1016/S0955-0674(97)80068-3PubMed
20.
Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A: Endothelial apoptosis in Braf-deficient mice. Nat Genet. 1997, 16: 293-297.PubMed
21.
Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC: Abnormal angiogenesis and response to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature. 1997, 386: 403-407.PubMed
22.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W: Mutations of the BRAF gene in human cancer. Nature. 2002, 417: 949-954. 10.1038/nature00766PubMed
23.
Reuther GW, Der CJ: The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol. 2000, 12: 157-165. 10.1016/S0955-0674(99)00071-XPubMed
24.
Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 1989, 49: 4682-4689.PubMed
25.
Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D: Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene. 2001, 20: 7624-7634. 10.1038/sj.onc.1204972PubMed
26.
Berra E, Milanini J, Richard DE, Le Gall M, Vinals F, Gothie E, Roux D, Pages G, Pouyssegur J: Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol. 2000, 60: 1171-1178. 10.1016/S0006-2952(00)00423-8PubMed
27.
Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000, 406: 532-535. 10.1038/35020106PubMed
28.
Semenza GL: HIF-1, O(2), and the 3 PHDs. 2001. How animal cells signal hypoxia to the nucleus. Cell. 2001, 107: 1-3.PubMed
29.
Wang GL, Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995, 270: 1230-1237. 10.1074/jbc.270.3.1230PubMed
30.
Wenger RH: Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol. 2000, 203: 1253-1263.PubMed
31.
Wenger RH: Cellular adaptation to hypoxia: O 2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002, 16: 1151-1162. 10.1096/fj.01-0944revPubMed
32.
Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH: Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000, 19: 5435-5443. 10.1038/sj.onc.1203938PubMed
33.
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG: HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001, 292: 464-468.PubMed
34.
Mahon PC, Hirota K, Semenza GL: FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15: 2675-1686. 10.1101/gad.924501PubMedCentralPubMed
35.
Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002, 16: 1466-1471. 10.1101/gad.991402PubMedCentralPubMed
36.
Berra E, Pages G, Pouyssegur J: MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 2000, 19: 139-145.PubMed
37.
Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS: Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 2000, 60: 4010-4015.PubMed
38.
Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000, 14: 34-44.PubMedCentralPubMed
39.
Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000, 6: 1335-1340. 10.1038/82146PubMed
40.
Kaelin WG: How oxygen makes its presence felt. Genes Dev. 2002, 16: 1441-1445. 10.1101/gad.1003602PubMed
41.
Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991, 1072: 129-157. 10.1016/0304-419X(91)90011-9PubMed
42.
Rupec RA, Baeuerle PA: The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-κB. Eur J Biochem. 1995, 234: 632-640.PubMed
43.
Yao KS, Xanthoudakis S, Curran T, O'Dwyer PJ: Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol. 1994, 14: 5997-6003.PubMedCentralPubMed
44.
Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, van Meir EG: Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene. 1999, 18: 1447-1456. 10.1038/sj.onc.1202424PubMed
45.
Kunz M, Hartmann A, Flory E, Toksoy A, Koczan D, Thiesen HJ, Mukaida N, Neumann M, Rapp UR, Bröcker EB, Gillitzer R: Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol. 1999, 155: 753-763.PubMedCentralPubMed
46.
Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M: HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life. 2001, 52: 49-53. 10.1080/15216540252774766PubMed
47.
Koong AC, Chen EY, Giaccia AJ: Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 1994, 54: 1425-1430.PubMed
48.
Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA: Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. NF-κB signalling. Cell. 1996, 86: 787-798.PubMed
49.
Damert A, Ikeda E, Risau W: Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J. 1997, 327: 419-423.PubMedCentralPubMed
50.
Laderoute KR, Calaoagan JM, Gustafson-Brown C, Knapp AM, Li GC, Mendonca HL, Ryan HE, Wang Z, Johnson RS: The response of c-jun/AP-1 to chronic hypoxia is hypoxia-inducible factor 1 alpha dependent. Mol Cell Biol. 2002, 22: 2515-2523. 10.1128/MCB.22.8.2515-2523.2002PubMedCentralPubMed
51.
Alfranca A, Gutierrez MD, Vara A, Aragones J, Vidal F, Landazuri MO: c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol. 2002, 22: 12-22. 10.1128/MCB.22.1.12-22.2002PubMedCentralPubMed
52.
Berg JM: Sp1 and the subfamily of zinc finger proteins with guanine-rich binding sites. Proc Natl Acad Sci U S A. 1992, 89: 11109-11110.PubMedCentralPubMed
53.
Xu Q, Ji YS, Schmedtje JF: Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure. J Biol Chem. 2000, 275: 24583-24589. 10.1074/jbc.M003894200PubMed
54.
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-364.PubMed
55.
Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 407: 249-257. 10.1038/35025220PubMed
56.
Folkman J, Klagsbrun M: Angiogenic factors. Science. 1987, 235: 442-447.PubMed
57.
Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994, 79: 185-188.PubMed
58.
Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM: CXC chemokines in angiogenesis. J Leukoc Biol. 2000, 68: 1-8.PubMed
59.
Rak J, Yu JL, Klement G, Kerbel RS: Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc. 2000, 5: 24-33. 10.1046/j.1087-0024.2000.00012.xPubMed
60.
Singh RK, Gutman M, Radinsky R, Bucana CD, Fiedler IJ: Expression of interleukin-8 correlates withe metastatic potential of human melanoma cells in nude mice. Cancer Res. 1994, 54: 3242-3247.PubMed
61.
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992, 359: 843-845.PubMed
62.
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996, 16: 4604-4613.PubMedCentralPubMed
63.
Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, Lyn P, Leavy J, Witte L, Joseph-Silverstein J: Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci U S A. 1995, 92: 4606-4610.PubMedCentralPubMed
64.
Hartmann A, Kunz M, Köstlin S, Gillitzer R, Toksoy A, Bröcker EB, Klein CE: Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res. 1999, 59: 1578-1583.PubMed
65.
Xu L, Xie K, Mukaida N, Matsushima K, Fidler IJ: Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res. 1999, 59: 5822-5829.PubMed
66.
Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ: Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000, 60: 883-887.PubMed
67.
Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ, Riggins GJ: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 2001, 93: 1337-1343. 10.1093/jnci/93.17.1337PubMed
68.
Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, van Meir EG: Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med. 1997, 8: 1201-1212. 10.1084/jem.186.8.1201.
69.
Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997, 3: 1222-1227.PubMed
70.
Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989, 246: 1309-1312.PubMed
71.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995, 376: 62-66.PubMed
72.
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature. 1992, 359: 845-848.PubMed
73.
Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996, 56: 172-181.PubMed
74.
Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL: Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985, 24: 5480-5486.PubMed
75.
Hu GF, Riordan JF, Vallee BL: A putative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc Natl Acad Sci U S A. 1997, 94: 2204-2209. 10.1073/pnas.94.6.2204PubMedCentralPubMed
76.
Olson KA, Fett JW, French TC, Key ME, Vallee BL: Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA. 1995, 92: 442-446.PubMedCentralPubMed
77.
Baggiolini M, Dewald B, Moser B: Human chemokines: an update. Annu Rev Immunol. 1997, 15: 675-705. 10.1146/annurev.immunol.15.1.675PubMed
78.
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophage derived mediator of angiogenesis. Science. 1992, 258: 1798-1801.PubMed
79.
Mukaida N, Mahe Y, Matsushima K: Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem. 1990, 265: 21128-21133.PubMed
80.
O'Brien TP, Yang GP, Sanders L, Lau LF: Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol. 1990, 10: 3569-3577.PubMedCentralPubMed
81.
Perbal B: NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol. 2001, 54: 57-79. 10.1136/mp.54.2.57PubMedCentralPubMed
82.
Babic AM, Kireeva ML, Kolesnikova TV, Lau LF: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1998, 95: 6355-6360. 10.1073/pnas.95.11.6355PubMedCentralPubMed
83.
Tsai MS, Hornby AE, Lakins J, Lupu R: Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 2000, 60: 5603-5607.PubMed
84.
Shimo T, Kubota S, Kondo S, Nakanishi T, Sasaki A, Mese H, Matsumura T, Takigawa M: Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett. 2001, 174: 57-64. 10.1016/S0304-3835(01)00683-8PubMed
85.
Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995, 1: 149-153.PubMed
86.
Barnhill RL, Piepkorn MW, Cochran AJ, Flynn E, Karaoli T, Folkman J: Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol. 1998, 134: 991-994. 10.1001/archderm.134.8.991PubMed
87.
Saikumar P, Dong Z, Weinberg JM, Venkatachalam MA: Mechanisms of cell death in hypoxia/reoxygenation injury. Oncogene. 1998, 17: 3341-3349. 10.1038/sj.onc.1202579PubMed
88.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997, 91: 479-489.PubMed
89.
Saikumar P, Dong Z, Patel Y, Hall K, Hopfer U, Weinberg JM, Venkatachalam MA: Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene. 1998, 17: 3401-3415. 10.1038/sj.onc.1202590PubMed
90.
Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y: Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature. 1995, 374: 811-813.PubMed
91.
Jacobson MD, Raff MC: Programmed cell death and Bcl-2 protection in very low oxygen. Nature. 1995, 374: 814-816.PubMed
92.
Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A. 2000, 97: 9082-9087. 10.1073/pnas.97.16.9082PubMedCentralPubMed
93.
Malhotra R, Lin Z, Vincenz C, Brosius FC 3rd: Hypoxia induces apoptosis via two independent pathways in Jurkat cells: differential regulation by glucose. Am J Physiol Cell Physiol. 2001, 281: C1596-C1603.PubMed
94.
Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC: Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene. 2000, 19: 4604-4610.PubMed
95.
Shim H, Chun YS, Lewis BC, Dang CV: A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A. 1998, 95: 1511-1516. 10.1073/pnas.95.4.1511PubMedCentralPubMed
96.
Schmaltz C, Hardenbergh PH, Wells A, Fisher DE: Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol. 1998, 18: 2845-2854.PubMedCentralPubMed
97.
An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature. 1998, 392: 405-408. 10.1038/32925PubMed
98.
Suzuki H, Tomida A, Tsuruo T: Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene. 2001, 20: 5779-5788. 10.1038/sj.onc.1204742PubMed
99.
Marte BM, Downward J: PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997, 22: 355-358. 10.1016/S0968-0004(97)01097-9PubMed
100.
Mayo LD, Donner DB: The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002, 27: 462-467. 10.1016/S0968-0004(02)02166-7PubMed
101.
Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, del Peso L: Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem. 2001, 276: 22368-22374. 10.1074/jbc.M011688200PubMed
102.
Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, Testa JR: AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene. 2002, 21: 3532-3540. 10.1038/sj.onc.1205438PubMed
103.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997, 15: 356-362.PubMed
104.
Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997, 57: 4187-4190.PubMed
105.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275: 1943-1947. 10.1126/science.275.5308.1943PubMed
106.
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997, 16: 64-67.PubMed
107.
Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998, 95: 13513-13518. 10.1073/pnas.95.23.13513PubMedCentralPubMed
108.
Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000, 14: 391-396.PubMedCentralPubMed
109.
Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW: Regulation of PTEN transcription by p53. Mol Cell. 2001, 8: 317-325.PubMed
110.
Alarcon R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ: Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999, 59: 6046-6051.PubMed
111.
Ashcroft M, Taya Y, Vousden KH: Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol. 2000, 20: 3224-3233. 10.1128/MCB.20.9.3224-3233.2000PubMedCentralPubMed
Metadata
Title
Molecular responses to hypoxia in tumor cells
Authors
Manfred Kunz
Saleh M Ibrahim
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2003
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-2-23

Other articles of this Issue 1/2003

Molecular Cancer 1/2003 Go to the issue

Review

The relationship between diabetes and pancreatic cancer

Review

What is the origin of pancreatic adenocarcinoma?

Research

Expression of CAAT Enhancer Binding Protein Beta (C/EBP β) in Cervix and Endometrium

Editorial

Cancer cachexia

Research

Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro

Review

Genetic alterations in pancreatic carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits